Premium
Motor vehicle accidents in Parkinson's disease: A questionnaire study
Author(s) -
Ueno T.,
Kon T.,
Haga R.,
Nishijima H.,
Tomiyama M.
Publication year - 2018
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.12849
Subject(s) - epworth sleepiness scale , excessive daytime sleepiness , logistic regression , psychology , parkinson's disease , medicine , physical therapy , disease , sleep disorder , psychiatry , polysomnography , cognition , apnea
Objectives Few studies have investigated the risk factors for motor vehicle accidents ( MVA ) in individuals with Parkinson's disease ( PD ) in Japan. Materials and Methods We sent an anonymous questionnaire to 1417 patients with PD who had received medical care certificates for Intractable Diseases during the 2014 fiscal year from the Aomori Prefectural Government in Japan. Data from patients with PD who previously or currently held a driving license at the time of the survey were analyzed. Results Complete datasets were obtained from 384 patients with PD who were either past or present driving license holders. Fifty‐seven patients had caused at least one MVA in the last 5 years before the survey. Logistic regression analyses revealed that ergot‐dopamine agonist ( DA ) use and excessive daytime sleepiness (Epworth Sleepiness Scale score ≥ 10) were the best predictors of MVA s. Patients having caused non‐sleep‐related MVA s had significantly longer disease durations, more frequent ergot‐ DA use, and higher cognition and communication subscores on the Parkinson's Disease Questionnaire‐39 than those without non‐sleep‐related MVA s ( P < .05). The Epworth Sleepiness Scale scores of PD patients with sleep‐related MVA s were significantly higher than those of patients without sleep‐related MVA s ( P < .01). Conclusions Excessive daytime sleepiness and ergot‐ DA use may be important predictive risk factors for MVA s in PD . Daytime sleepiness appears to be related to sleep‐related MVA s in PD , whereas disease progression and ergot‐ DA use may contribute to non‐sleep‐related MVA s.